218 related articles for article (PubMed ID: 37042938)
1. CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis.
Xu X; Dennett P; Zhang J; Sherrard A; Zhao Y; Masubuchi T; Bui JD; Chen X; Hui E
J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37042938
[TBL] [Abstract][Full Text] [Related]
2. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
3. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
5. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
6. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
[TBL] [Abstract][Full Text] [Related]
7. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
8. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
9. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
10. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
11. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
12. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.
Vaughan AN; Malde P; Rogers NJ; Jackson IM; Lechler RI; Dorling A
J Immunol; 2000 Sep; 165(6):3175-81. PubMed ID: 10975832
[TBL] [Abstract][Full Text] [Related]
13. Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4.
Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Immunol; 2001 Mar; 166(5):3107-13. PubMed ID: 11207262
[TBL] [Abstract][Full Text] [Related]
14. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
15. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
Murata K; Dalakas MC
Am J Pathol; 1999 Aug; 155(2):453-60. PubMed ID: 10433938
[TBL] [Abstract][Full Text] [Related]
16. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
17. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses.
Blazevic V; Trubey CM; Shearer GM
J Clin Immunol; 2001 Jul; 21(4):293-302. PubMed ID: 11506200
[TBL] [Abstract][Full Text] [Related]
19. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
20. Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cells.
Wong C; Darby JM; Murphy PR; Pinfold TL; Lennard PR; Woods GM; Lyons AB; Flies AS
Dev Comp Immunol; 2021 Feb; 115():103882. PubMed ID: 33039410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]